FacebookTwitterGoogle+RedditEmail

Protecting Bones from Drugs that Protect Bones

Like gastro-esophageal reflux and bipolar disease, osteopenia began to inflict millions when a drug to treat it came on patent.

Osteopenia or the risk of developing osteoporosis was concocted as a disease at a World Health Organization (WHO) osteoporosis conference in Rome in 1992 sponsored by two drug companies and a drug-company foundation writes Susan Kelleher in the Seattle Times.

Using the bone density measurements or “T scores” of a 30-year-old woman as a standard, the new condition, osteopenia, had “boundaries so broad they include more than half of all women over 50,” writes Kelleher. And it didn’t hurt that 10,000 bone density measuring machines appeared in doctors’ offices by 1999 to detect the new disease–only 750 existed previously–many owned and financed by Merck whose anti bone-thinning drug Fosamax came online in 1995.

No wonder doctor visits for thinning bones increased by five million from 1994 to 2003 according to the Associated Press.

Of course selling “prevention” to at risk patients is a pharma goldmine.

It keep patients on meds for decades through fear, alarmist marketing and after-this-because-of-this reasoning–since a patient doesn’t know if she would have gotten the disease anyway.

So even when reports of Fosamax-related jaw problems called osteonecrosis surfaced–1,000 cases have been documented–and even when a study in the Archives of Internal Medicine this year found Fosamax doubled women’s risk of irregular heart beat which can cause clots and strokes, few doubted its primary action of protecting women’s bones.

But now, like hormone replacement therapy which also exploited women’s fear of aging and social marginalization, Fosamax appears to cause the conditions it’s supposed to prevent.

Since 2006, articles in the New England Journal of Medicine, Journal of Orthopedic Trauma, Journal of Bone and Joint Surgery, Journal of Clinical Endocrinology & Metabolism, Aging Clinical and Experimental Research, Hong Kong Medical Journal, Geriatrics and Bone have suggested the anti-bone turnover action of bisphosphonate drugs like Fosamax can in some cases cause fractures.

Oops.

Sure bisphosphonates prevent bone loss that is caused by the process of bone turnover or remodeling. But they also fossilize and petrify a bone so it breaks spontaneously and with minimal trauma–like chalk–scientists now say. Nor will it heal properly.

Thighbones of patients on bisphosphonates have “simply snapped while they were walking or standing,” reported the New York Times in July following “weeks or months of unexplained aching.”

Like other fast-tracked-to-Wall-Street drugs which are effectively “tested” on the first users, adverse reports about bisphosphonates came from patients and practitioners long before the FDA or manufacturers.

Bisphosphonate patients documented excruciating pain from Fosamax since 2001 and GlaxoSmithKline’s Boniva since 2006 on askapatient.com, many calling the drugs “poison” and saying they were forced into wheelchairs.

But only in March did the FDA alert healthcare professionals to the, “severe, sometimes incapacitating musculoskeletal pain” bisphosphonate drugs could cause in their patients and caution them to consider whether musculoskeletal pain “might be caused by the drug” not the bone condition.

Not only is the pain bisphosphonate patients report “not in their heads”–imagine 1,257 men on askapatient.com saying their doc dismissed their constant pain and symptomology–it is emblematic of what is really going on.

“There is actually bone death occurring,” Dr. Phuli Cohan told Mallika Marshall, MD Medical Reporter for Boston’s WBZ-TV News in May. “People don’t want to believe that this is happening, but it is a side effect of the medicine,” she said.

Dr. David Hunter of the New England Baptist Hospital concurs that bisphosphonates can cause “Dead Bone Syndrome” and patients should have a “drug holiday to allow bone cells to rejuvenate,” reports Marshall.

Even drug reps on industry chatroom cafepharma are skeptical about bisphosphonates.

“They over suppress the bone and ‘may’ cause sub trochanter fractures,” wrote one anonymous poster on a thread called “Is Boniva dead” sparked by a rumor that Boniva pitchwoman Sally Fields had fallen and broken a bone. “It’s the next hot button.”

Nor do bisphosphonates exit the body quickly when patients quit according to a 2006 study in the Journal of the American Medical Association–but remain for years.

(Patients “need not take costly bone-building drugs such as Fosamax for life to reap the medicine’s protective benefits,” was the News & Observer’s upbeat interpretation of the drug’s tenacity.)

If bisphosphonates prove to be the next hormone replacement therapy–causing the conditions they were supposed to treat–the osteopenia epidemic will no doubt clear up.

Especially since the patents are running out.

MARTHA ROSENBERG is staff cartoonist on the Evanston Roundtable. She can be reached at mrosenberg@evmark.org

 

 

 

 

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

April 25, 2018
Stanley L. Cohen
Selective Outrage
Dan Kovalik
The Empire Turns Its Sights on Nicaragua – Again!
Joseph Essertier
The Abductees of Japan and Korea
Ramzy Baroud
The Ghost of Herut: Einstein on Israel, 70 Years Ago
W. T. Whitney
Imprisoned FARC Leader Faces Extradition: Still No Peace in Colombia
Manuel E. Yepe
Washington’s Attack on Syria Was a Mockery of the World
John White
My Silent Pain for Toronto and the World
Dean Baker
Bad Projections: the Federal Reserve, the IMF and Unemployment
David Schultz
Why Donald Trump Should Not be Allowed to Pardon Michael Cohen, His Friends, or Family Members
Mel Gurtov
Will Abe Shinzo “Make Japan Great Again”?
Binoy Kampmark
Enoch Powell: Blood Speeches and Anniversaries
Frank Scott
Weapons and Walls
April 24, 2018
Carl Boggs
Russia and the War Party
William A. Cohn
Carnage Unleashed: the Pentagon and the AUMF
Nathan Kalman-Lamb
The Racist Culture of Canadian Hockey
María Julia Bertomeu
On Angers, Disgusts and Nauseas
Nick Pemberton
How To Buy A Seat In Congress 101
Ron Jacobs
Resisting the Military-Now More Than Ever
Paul Bentley
A Velvet Revolution Turns Bloody? Ten Dead in Toronto
Sonali Kolhatkar
The Left, Syria and Fake News
Manuel E. Yepe
The Confirmation of Democracy in Cuba
Peter Montgomery
Christian Nationalism: Good for Politicians, Bad for America and the World
Ted Rall
Bad Drones
Jill Richardson
The Latest Attack on Food Stamps
Andrew Stewart
What Kind of Unionism is This?
Ellen Brown
Fox in the Hen House: Why Interest Rates Are Rising
April 23, 2018
Patrick Cockburn
In Middle East Wars It Pays to be Skeptical
Thomas Knapp
Just When You Thought “Russiagate” Couldn’t Get Any Sillier …
Gregory Barrett
The Moral Mask
Robert Hunziker
Chemical Madness!
David Swanson
Senator Tim Kaine’s Brief Run-In With the Law
Dave Lindorff
Starbucks Has a Racism Problem
Uri Avnery
The Great Day
Nyla Ali Khan
Girls Reduced to Being Repositories of Communal and Religious Identities in Kashmir
Ted Rall
Stop Letting Trump Distract You From Your Wants and Needs
Steve Klinger
The Cautionary Tale of Donald J. Trump
Kevin Zeese - Margaret Flowers
Conflict Over the Future of the Planet
Cesar Chelala
Gideon Levy: A Voice of Sanity from Israel
Weekend Edition
April 20, 2018
Friday - Sunday
Paul Street
Ruling Class Operatives Say the Darndest Things: On Devils Known and Not
Conn Hallinan
The Great Game Comes to Syria
Jeffrey St. Clair
Roaming Charges: Mother of War
Andrew Levine
“How Come?” Questions
Doug Noble
A Tale of Two Atrocities: Douma and Gaza
Kenneth Surin
The Blight of Ukania
Howard Lisnoff
How James Comey Became the Strange New Hero of the Liberals
FacebookTwitterGoogle+RedditEmail